Published in Cancer Res on July 01, 2003
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol (2012) 2.02
Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. J Biol Chem (2008) 2.02
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev (2008) 1.91
The oncofetal Thomsen-Friedenreich carbohydrate antigen in cancer progression. Glycoconj J (2007) 1.74
Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential. Am J Pathol (2006) 1.61
Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett (2014) 1.55
Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia (2005) 1.48
Tumour-associated carbohydrate antigens in breast cancer. Breast Cancer Res (2010) 1.41
Phage display in molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.34
The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. Am J Pathol (2008) 1.33
Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res (2008) 1.28
MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis (2005) 1.23
Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer (2010) 1.23
Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. Neoplasia (2006) 1.23
Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Int J Cancer (2011) 1.21
Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle (2006) 1.21
Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp Cell Res (2007) 1.17
Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. J Physiol (2004) 1.14
Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia (2007) 1.08
High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer (2010) 1.05
Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res (2010) 1.03
Microtentacles tip the balance of cytoskeletal forces in circulating tumor cells. Cancer Res (2010) 1.01
Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology (2008) 1.00
Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine. Neoplasia (2012) 0.97
Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin. Oncogene (2012) 0.96
Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J Biol Chem (2012) 0.96
Spheroid Culture of Mesenchymal Stem Cells. Stem Cells Int (2015) 0.96
Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo. Neoplasia (2009) 0.95
Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res (2013) 0.93
Dynamic regulation of ROCK in tumor cells controls CXCR4-driven adhesion events. J Cell Sci (2010) 0.93
Circulating galectin-3 in the bloodstream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol (2010) 0.91
A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction. Glycobiology (2009) 0.91
Intercellular adhesion: mechanisms for growth and metastasis of epithelial cancers. Wiley Interdiscip Rev Syst Biol Med (2011) 0.90
Analysis of differential expression of glycosyltransferases in healing corneas by glycogene microarrays. Glycobiology (2009) 0.88
An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One (2013) 0.88
Expected clinical applications of circulating tumor cells in breast cancer. World J Clin Oncol (2011) 0.87
Immunomagnetic enrichment of disseminated tumor cells in bone marrow and blood of breast cancer patients by the Thomsen-Friedenreich-Antigen. Clin Exp Metastasis (2008) 0.86
Metastatic tumor cell arrest in the liver-lumen occlusion and specific adhesion are not exclusive. Int J Colorectal Dis (2009) 0.85
MUC1 is involved in trophoblast transendothelial migration. Biochim Biophys Acta (2007) 0.85
Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J Exp Clin Cancer Res (2011) 0.85
Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J Gastroenterol (2012) 0.84
Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells. Clin Exp Metastasis (2014) 0.84
Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release (2015) 0.83
Galectins in tumor angiogenesis. Ann Transl Med (2014) 0.83
The two endocytic pathways mediated by the carbohydrate recognition domain and regulated by the collagen-like domain of galectin-3 in vascular endothelial cells. PLoS One (2012) 0.82
Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen-Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J (2008) 0.82
The inhibitory effects of a rhamnogalacturonan I (RG-I) domain from ginseng pectin on galectin-3 and its structure-activity relationship. J Biol Chem (2013) 0.82
ROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cells. Oncotarget (2015) 0.81
Galectins in hematological malignancies. Am J Blood Res (2011) 0.81
Tumor-associated glycans and their role in gynecological cancers: accelerating translational research by novel high-throughput approaches. Metabolites (2012) 0.81
Analysis of the neutral polysaccharide fraction of MCP and its inhibitory activity on galectin-3. Glycoconj J (2012) 0.81
Phenotypic drug profiling in droplet microfluidics for better targeting of drug-resistant tumors. Lab Chip (2015) 0.80
Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis. Oncotarget (2015) 0.78
Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clin Exp Metastasis (2012) 0.78
Three-dimensional chemotaxis-driven aggregation of tumor cells. Sci Rep (2015) 0.78
Gene silencing of galectin-3 changes the biological behavior of Eca109 human esophageal cancer cells. Mol Med Rep (2015) 0.77
A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis. Oncogene (2011) 0.77
Synthesis and cell-selective antitumor properties of amino acid conjugated tumor-associated carbohydrate antigen-coated gold nanoparticles. Carbohydr Res (2014) 0.76
Expression of antigen tf and galectin-3 in fibroadenoma. BMC Res Notes (2012) 0.75
Circulating tumor cell clusters: What we know and what we expect (Review). Int J Oncol (2016) 0.75
When Prostate Cancer Circulates in the Bloodstream. Diagnostics (Basel) (2015) 0.75
Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun (2017) 0.75
Interaction of the Oncofetal Thomsen-Friedenreich Antigen with Galectins in Cancer Progression and Metastasis. Front Oncol (2016) 0.75
Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. Oncogene (2016) 0.75
Synergistic interaction between galectin-3 and carcinoembryonic antigen promotes colorectal cancer metastasis. Oncotarget (2017) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Population diversity and the portfolio effect in an exploited species. Nature (2010) 6.88
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Biocomplexity and fisheries sustainability. Proc Natl Acad Sci U S A (2003) 5.01
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A (2008) 4.07
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem (2007) 3.38
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem (2009) 2.81
The current state of hormonal therapy for prostate cancer. CA Cancer J Clin (2002) 2.74
Evolution of cooperation among tumor cells. Proc Natl Acad Sci U S A (2006) 2.63
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62
Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol (2007) 2.53
Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res (2010) 2.41
Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res (2007) 2.31
Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol (2002) 2.31
Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet (2013) 2.30
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
Networks of intergenic long-range enhancers and snpRNAs drive castration-resistant phenotype of prostate cancer and contribute to pathogenesis of multiple common human disorders. Cell Cycle (2011) 2.19
Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res (2007) 2.14
CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia (2006) 2.05
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Randomized clinical trial of a family intervention for prostate cancer patients and their spouses. Cancer (2007) 2.02
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
Evidence for geomagnetic imprinting as a homing mechanism in Pacific salmon. Curr Biol (2013) 1.93
CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia (2007) 1.91
Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res (2004) 1.82
99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med (2007) 1.81
The evolving biology and treatment of prostate cancer. J Clin Invest (2007) 1.81
Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet (2004) 1.80
In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther (2003) 1.77
Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem (2008) 1.74
Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst (2010) 1.74
The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia (2002) 1.72
CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation. J Biol Chem (2008) 1.71
MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia (2002) 1.71
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle (2006) 1.69
Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res (2005) 1.66
Stromal factors involved in prostate carcinoma metastasis to bone. Cancer (2003) 1.63
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res (2009) 1.61
Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun (2013) 1.61
Eco-evolutionary vs. habitat contributions to invasion in salmon: experimental evaluation in the wild. Mol Ecol (2007) 1.61
Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes. Blood (2008) 1.60
Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues. Bioconjug Chem (2003) 1.58
Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res (2012) 1.58
GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (2010) 1.56
Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate (2007) 1.56
Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype. Mol Cancer Res (2012) 1.55
An evaluation of the effects of conservation and fishery enhancement hatcheries on wild populations of salmon. Adv Mar Biol (2007) 1.54
An in vivo mouse model for human prostate cancer metastasis. Neoplasia (2008) 1.54
Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials (2009) 1.54
Melanoma therapy via peptide-targeted {alpha}-radiation. Clin Cancer Res (2005) 1.52
A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia (2007) 1.50
Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem (2005) 1.49
The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia (2009) 1.49
Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia (2005) 1.48
111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide analogues for melanoma imaging. Bioconjug Chem (2008) 1.48
The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin (2007) 1.46
A sequence-based survey of the complex structural organization of tumor genomes. Genome Biol (2008) 1.45
Erythropoietin couples hematopoiesis with bone formation. PLoS One (2010) 1.44
Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44
A glycolytic mechanism regulating an angiogenic switch in prostate cancer. Cancer Res (2007) 1.43
Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med (2007) 1.42
Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A (2004) 1.42
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med (2005) 1.41
Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking. Proc Natl Acad Sci U S A (2009) 1.40
Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate (2008) 1.37
In vivo evaluation of 188Re-labeled alpha-melanocyte stimulating hormone peptide analogs for melanoma therapy. Int J Cancer (2002) 1.37
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A (2013) 1.37
Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol (2006) 1.33
Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer. PLoS One (2013) 1.32
Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res (2005) 1.31
Exercise training regulates SOD-1 and oxidative stress in porcine aortic endothelium. Am J Physiol Heart Circ Physiol (2002) 1.30